DCFPyL
Phase 2Small molecule
DCFPyL is one of 31 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Radium-223
BayerPhase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
DCFPyL
SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Solid Tumors1 trial
Multimodal Machine Learning Characterization of Solid Tumors
Active, not recruiting·—··NCT04687969·135 enrolled
Brachytherapy1 trial
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03861676·20 enrolled
Prostate Cancer1 trial
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Active, not recruiting·—·Phase 2·NCT03585114·11 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DCFPyL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details